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Abstract
Background: As crucial regulators of the immune response against pathogens, macrophages have been extensively
shown also to be important players in several diseases, including cancer. Specifically, breast cancer macrophages tightly
control the angiogenic switch and progression to malignancy. ID4, a member of the ID (inhibitors of differentiation)
family of proteins, is associated with a stem-like phenotype and poor prognosis in basal-like breast cancer. Moreover,
ID4 favours angiogenesis by enhancing the expression of pro-angiogenic cytokines interleukin-8, CXCL1 and vascular
endothelial growth factor. In the present study, we investigated whether ID4 protein exerts its pro-angiogenic function
while also modulating the activity of tumour-associated macrophages in breast cancer.
Methods: We performed IHC analysis of ID4 protein and macrophage marker CD68 in a triple-negative breast cancer
series. Next, we used cell migration assays to evaluate the effect of ID4 expression modulation in breast cancer cells on
the motility of co-cultured macrophages. The analysis of breast cancer gene expression data repositories allowed us to
evaluate the ability of ID4 to predict survival in subsets of tumours showing high or low macrophage infiltration.
By culturing macrophages in conditioned media obtained from breast cancer cells in which ID4 expression was
modulated by overexpression or depletion, we identified changes in the expression of ID4-dependent angiogenesis-
related transcripts and microRNAs (miRNAs, miRs) in macrophages by RT-qPCR.
Results: We determined that ID4 and macrophage marker CD68 protein expression were significantly associated in a
series of triple-negative breast tumours. Interestingly, ID4 messenger RNA (mRNA) levels robustly predicted survival,
specifically in the subset of tumours showing high macrophage infiltration. In vitro and in vivo migration assays
demonstrated that expression of ID4 in breast cancer cells stimulates macrophage motility. At the molecular level,
ID4 protein expression in breast cancer cells controls, through paracrine signalling, the activation of an angiogenic
programme in macrophages. This programme includes both the increase of angiogenesis-related mRNAs and the
decrease of members of the anti-angiogenic miR-15b/107 group. Intriguingly, these miRNAs control the expression
of the cytokine granulin, whose enhanced expression in macrophages confers increased angiogenic potential.
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Conclusions: These results uncover a key role for ID4 in dictating the behaviour of tumour-associated macrophages in
breast cancer.
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Background
Breast cancer (BC) is the most common cancer in
women worldwide and remains a leading cause of cancer
death [1]. It is a heterogeneous disease with multiple
subtypes that display different patterns of gene expres-
sion, prognosis and response to treatment [2]. Metasta-
sis, which is responsible for over 90% of BC deaths, is
regulated to a great extent by reciprocal interactions be-
tween cancer cells and immune cells in the tumour
microenvironment [3, 4].
Tumour-associated macrophages (TAMs), which are
part of the adaptive immune response, constitute a
major portion of the leucocyte infiltrate found in breast
tumours and tightly control angiogenic switch and
progression to malignancy in BC [5]. Tumour cells ac-
tively recruit macrophages and educate them to be
pro-tumourigenic [6, 7]. TAMs exhibit potent prolifera-
tive capacity upon their differentiation from inflamma-
tory monocytes, and the presence of intra-tumoural
proliferating macrophages was significantly correlated
with high-grade, hormone receptor-negative tumours
and a basal-like subtype of BC [7, 8]. The number of
proliferating macrophages was also a significant pre-
dictor of recurrence and survival [9].
Several reports suggest that TAMs adopt a trophic
immunosuppressive phenotype that is functionally remin-
iscent of the alternatively activated type II (M2) macro-
phages [10]. However, TAMs present great phenotypic
diversity depending on the combinations of stimuli re-
ceived in the tumour stroma, and it has been proposed
that multiple subpopulations of TAMs exist within tu-
mours, which probably change temporally during tumour
development and geographically on the basis of their loca-
tion within the tumour microenvironment [11, 12].
Functionally, TAMs have been shown to facilitate tumour
angiogenesis, invasion, intravasation and metastasis in ani-
mal models [13, 14] and are now recognised as important
therapeutic targets in the treatment of cancer [15].
ID4 is a member of the ID family of proteins (inhibi-
tors of differentiation, ID-1 to ID-4) that act as
dominant-negative regulators of basic helix-loop-helix
transcription factors [16]. Studies have indicated that ID
proteins are associated with loss of differentiation, stem-
ness, unrestricted proliferation, and neoangiogenesis in
diverse human cancers. In the context of BC, ID4 is
highly expressed in triple-negative breast cancer
(TNBC), 70% of which belong to the basal-like breast
cancer (BLBC) molecular subtype [17, 18]. Accordingly,
ID4 was repeatedly identified as a component of
BLBC-associated molecular signatures [19]. Recent evi-
dence suggests an emerging role for ID4 as a
lineage-dependent proto-oncogene that is overexpressed
and amplified in BLBCs and is associated with stem-like
phenotype and poor prognosis in this subtype and in
TNBC [17, 20–23].
At the molecular level, ID4 has been shown to be re-
sponsible for the downregulation of BRCA1 promoter
activity [24], and consequently, ID4 expression is in-
versely correlated with that of BRCA1 [20, 23, 25, 26]. In
addition, clinical data have indicated preferential ID4
amplification in BRCA1 mutant cases [23, 27]. We previ-
ously reported that ID4 protein results in induction of
chemokine (C-X-C motif ) ligand 1 (CXCL1) and inter-
leukin (IL)-8 pro-angiogenic cytokines and in enhanced
angiogenic potential of BC [28, 29]. Moreover, mutant
p53 proteins transcriptionally induce ID4, and a complex
containing ID4 and mutant p53 proteins is responsible
for the synthesis of pro-angiogenic vascular endothelial
growth factor (VEGF) isoforms in BC [30].
To fully explore the mechanisms through which ID4
controls BC angiogenesis, we investigated whether it was
able to modulate TAM activity. We report that ID4 ex-
pression in BC cells is indeed able to reprogramme the
expression of angiogenesis-related genes in macrophages
through a paracrine VEGF-dependent effect. In particu-
lar, we observed the ID4-dependent induction of
hypoxia-inducible factor (HIF)-1A, whose expression in
macrophages suppresses T-cell function and promotes
progression in BC [31], and of granulin (GRN), which
was previously reported to control macrophage activity
in autoimmune diseases [32]. Of note, microRNAs
(miRNAs, miRs) of the miR-15b/107 group, which target
these angiogenesis-related factors, were concomitantly
downregulated. Our data also showed that high ID4
mRNA expression level is associated with reduced dis-
tant metastasis-free survival (DMFS) and overall survival
(OS), specifically in patients carrying tumours highly in-
filtrated by macrophages.
Methods
Cell cultures and transfections
The SKBR3, MDA-MB-468, HL60 and U937 cell lines
were grown at 37 °C with 5% CO2 and maintained in
RPMI medium containing 10% heat-inactivated FBS and
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penicillin/streptomycin. HL60 and U937 cells were dif-
ferentiated by treatment with 1,25-dihydroxyvitamin D3
(VitD3) (Sigma-Aldrich, St. Louis, MO, USA) at a con-
centration of 250 ng/ml. Monocytic differentiation was
assessed by fluorescence-activated cell sorting (FACS)
as previously reported [33] using allophycocyanin
(APC) anti-human CD11b (BD Biosciences, San Jose,
CA, USA), PerCP-Cy5.5 (peridinin chlorophyll protein
complex-cyanine 5.5) anti-human CD14 (BD Biosciences)
and phycoerythrin-immunoglobulin G1 (PE-IgG1) isotype
control (eBioscience Inc., San Diego, CA, USA) antibodies
for the evaluation of CD11b-CD14 co-expression as a
marker of monocytic differentiation. A minimum of
10,000 events were collected for each sample with a flow
cytometer (CyAN ADP; Beckman Coulter Life Sciences,
Brea, CA, USA) using Summit 4.3 software (Beckman
Coulter Life Sciences) for data acquisition and analysis.
An expression vector containing a hemagglutinin
(HA)-tagged ID4 coding sequence [28] or control
empty vector was transfected in cancer cells using Li-
pofectamine 2000 reagent (Thermo Fisher Scientific,
Waltham, MA, USA) in ID4 overexpression experi-
ments. RNAiMAX reagent (Thermo Fisher Scientific,
Waltham, MA, USA) was used to transfect small inter-
fering RNAs (siRNAs) in BC cells. Sequences of siRNAs
directed to ID4 were previously reported [30]. Mono-
cytic cell lines were transfected with plasmids, mimic
and locked nucleic acid (LNA) oligonucleotides (Dhar-
macon, Lafayette, CO, USA) using the TransIT-X2® Dy-
namic Delivery System (Mirus Bio LLC, Madison, WI,
USA) following the manufacturer’s instructions.
Full-length cDNA (including 5′-UTR and 3′-UTR) of
human GRN (NM_002087.2), cloned in the
pCMV6-XL5 plasmid vector, was generously provided
by Dr. Peter Nelson.
Mouse bone marrow-derived macrophage precursors
were obtained from rodents by flushing the femurs and
tibias with 2% FBS in PBS. Differentiation was induced
by culturing precursors in colony-stimulating factor 1
(CSF1)-rich conditioned media (CM) derived from L929
fibroblast cell culture. Differentiation was evaluated by
FACS analysis using the following antibodies:
anti-mouse F4/80 antigen APC (17-4801; eBioscience),
Ly-6G (Gr-1) APC (17-5931; eBioscience, San Diego,
CA, USA), CD14 PE (12-0141; eBioscience, San Diego,
CA, USA) and CD107b (Mac-3) PE (12-5989;
eBioscience, San Diego, CA, USA).
Human peripheral blood-derived monocytes were iso-
lated from blood donors using Lymphoprep solution
(Axis-Shield, Dundee, UK) followed by isolation of
CD14+ cells with the Monocyte Isolation Kit II (Miltenyi
Biotec, Bergisch Gladbach, Germany). Differentiation
was achieved through 1-week culturing in RPMI
medium containing recombinant CSF1 (human
macrophage colony-stimulating factor, catalogue number
8929SC; Cell Signaling Technology, Danvers, MA, USA).
CM from BC cells were prepared by culturing cells for
24 hours in serum-free RPMI medium. CM were centri-
fuged to eliminate cell residues before preparation of ali-
quots and storage at − 80 °C. When si-ID4 BC cells were
used to prepare CM, we always collected CM before
48 hours from transfection because of proliferation of
cells being delayed after this time point in the si-ID4
condition (Additional file 1: Figure S3).
In vitro and in vivo macrophage migration assays
Migration of mouse bone marrow-derived macrophages
in response to SKBR3 cells was evaluated using
3-μm-pore Boyden chambers (Corning Inc., Corning,
NY, USA). Infiltration of F4/80+ macrophages in
Matrigel plugs containing CM from BC MDA-MB-468
cells was evaluated by subcutaneous inoculation of a so-
lution composed of 500 μl of Matrigel (BD Biosciences)
and 50 μl of a 10 × concentration of CM. In the negative
control, the CM was replaced with serum-free medium.
Plugs were recovered at day 7, fixed for 18–24 hours in
4% (vol/vol) buffered formaldehyde, and then processed
with paraffin wax. IHC was performed using F4/80 anti-
body (MA5-16363; Pierce Biotechnology, Rockford, IL,
USA). All procedures involving animals and their care
were conducted in conformity with institutional guide-
lines, which are in compliance with national and inter-
national standards.
IHC
Tumours from 62 patients included in this study were
previously described in a study by Novelli et al. [34], which
was reviewed and approved by the ethics committee of
the Regina Elena National Cancer Institute and contained
data for which written informed consent was obtained
from all patients. Characteristics of these patients are in-
cluded in Additional file 2: Table S1. BC specimens for
IHC analysis were fixed for 18–24 hours in 4% (vol/vol)
buffered formaldehyde and then processed with paraffin
wax. Anti-ID4 (MAB4393; EMD Millipore, Billerica, MA,
USA), anti-oestrogen receptor (clone 6F11; Novocastra,
Florence, Italy), anti-progesterone receptor (anti-PgR,
clone 1A6; Novocastra), and anti-HER2 (A0485; Dako,
Milan, Italy) were evaluated by IHC in 5-μm-thick
paraffin-embedded tissues. Monoclonal antibodies (mAb)
directed against ID4 were incubated at a dilution of 1:200
overnight at 4 °C, and anti-ER and anti-PgR mAb and the
polyclonal antibody anti-HER2 were incubated for 60 -
minutes at room temperature. Immunoreactions were
revealed by a streptavidin-biotin enhanced immunoperox-
idase technique (Super Sensitive MultiLink; BioGenex,
Fremont, CA, USA) in an autostainer (Bond III; Leica
Biosystems, Wetzlar, Germany). Diaminobenzidine (DAB)
Donzelli et al. Breast Cancer Research  (2018) 20:59 Page 3 of 15
was used as a chromogenic substrate. Evaluation of the
IHC data was performed independently and in a blinded
manner by two investigators (EG and EM).
Immunocytochemistry and immunofluorescence
For immunocytochemistry assay, cells were seeded onto
glass coverslips (Paul Marienfeld, Lauda-Königshofen,
Germany) in 6-well dishes (Corning Inc.) at 4 × 104 cells/
well, cultured with RPMI or CM, and fixed with 4%
formaldehyde in PBS for 15 minutes at room temperature.
Cells were permeabilized with 0.25% Triton X-100 in PBS
for 10 minutes. After washing with PBS, the coverslips
were incubated with anti-ID4 antibody diluted in 5% bo-
vine serum albumin (BSA)/PBS for 2 hours at room
temperature. Cells were incubated with peroxidase inhibi-
tor before primary antibody incubation. Protein staining
was revealed through DAB enzymatic reaction, and nuclei
were counterstained with haematoxylin.
For immunofluorescence, cells grown in the presence
of RPMI or CM (48 hours), as well as cells transfected
with mimic oligonucleotides (48 hours), were concen-
trated onto microscope slides using cytospin and fixed
and permeabilized as already described. Slides were
blocked for 30 minutes in 5% BSA/PBS at room
temperature and then incubated with an anti-HIF-1A
antibody (A300-286A; Bethyl Laboratories, Montgomery,
TX, USA) diluted in 5% BSA/PBS for 2 hours at room
temperature. Cells were incubated with secondary anti-
body Alexa Fluor 594 (1:500; Thermo Fisher Scientific)
for 45 minutes. Nuclei were stained with DAPI (Thermo
Fisher Scientific).
Western blotting and antibodies
For the Western blot analysis, cells were lysed in radio-
immunoprecipitation assay buffer or 8 M urea. The pro-
tein concentration was measured using a Bio-Rad
protein assay kit (Bio-Rad Laboratories, Hercules, CA,
USA). The lysate was mixed with 4 × Laemmli buffer.
Total protein extracts were resolved on polyacrylamide
gel and then transferred onto nitrocellulose membrane.
The following primary antibodies were used: Gapdh
(sc-32,233), ID4 (H70) sc-13047, ID4 (B5) sc-365656,
HA (12CA5) sc-57592 (Santa Cruz Biotechnology,
Dallas, TX, USA); HIF-1A (A300-286A; Bethyl
Laboratories); GRN (PA5-29909), EphB2 (PA5-14607),
and Mdk (PA5-30601; Thermo Fisher Scientific).
Secondary antibody fused with horseradish peroxidase
was used for chemiluminescence detection on a
UVITEC instrument (Uvitec, Cambridge, UK). VEGFA
blocking antibody (AF-293-NA; R&D Systems, Minneap-
olis, MN, USA) was added to CM and incubated for
30 minutes at room temperature before being used to
culture macrophages, following the manufacturer’s
instructions.
RNA isolation, RT-qPCR and TaqMan Low Density Arrays
RNA was isolated with TRIzol reagent (Sigma-Aldrich),
and its concentration was measured using a NanoDrop
2000 instrument (NanoDrop Technologies, Wilmington,
DE, USA). Reverse transcription was performed with
Moloney murine leukemia virus reverse transcriptase
(Thermo Fisher Scientific). qPCR was carried out on an
ABI PRISM 7500 Fast Sequence Detection System
(Applied Biosystems, Foster City, CA, USA). Primers
used for PCR analyses are available upon request. The
expression values of mRNAs were calculated by the
standard curve method and normalised with housekeep-
ing control genes (GAPDH, β-actin, H3). qPCR using
TaqMan Low Density Arrays (TLDA) Human Angiogen-
esis (4378725; Thermo Fisher Scientific) was carried out
following the manufacturer’s instructions on an ABI
PRISM 7900HT Sequence Detection System.
Angiogenic assay in zebrafish embryo
Four microlitres of CM was mixed with 4 μl of Growth
Factor Reduced Matrigel (BD Biosciences) and 0.5 μl of
phenol red. The mixture of CM and Matrigel was injected
into the perivitelline space of Tg(fli:EGFP) casper zebrafish
embryos at 48 hours post-fertilisation. The injection was
performed using glass micropipettes with capillaries of
0.75-mm internal diameter. The following parameters
were used for the micropipette puller (P-1000; Sutter In-
struments, Novato, CA, USA): heat 510, pull 100, velocity
200, time 40, and pressure 500. The parameters of the
PicoPump injector (World Precision Instruments, Sara-
sota, FL, USA) were set to inject 1 nl of CM. Within
24 hours after injection, the neovascular response origin-
ating from the developing subintestinal vessels was ob-
served on a fluorescence stereoscope.
Tube-formation assay
Differentiated U937 cells were transfected with siRNAs
directed to GRN mRNA or control siRNAs for 8 hours
and subsequently cultured with CM from MDA-MB-468
cells. After 72 hours of culture, CM was collected and
used to perform tube-formation assays as described by
Pruszko et al. [30].
Cell viability assay
Viability of U937 cells was assessed using the ATPlite
assay (PerkinElmer, Waltham, MA, USA) at the indi-
cated time point and according to the manufacturer’s in-
structions. Differentiated U937 cells (1 × 105 cells),
previously transfected with GRN expression vector, were
seeded into 96-well plates and cultured for 48 hours in
CM from MDA-MB-468 cells. Luminescence was read
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by using the EnSpire® Multimode Plate Reader
(PerkinElmer).
Results
ID4 expression correlates with macrophage recruitment
in triple-negative breast cancer
We previously demonstrated that ID4 protein expression
is associated with high microvessel density in BC.
Mechanistically, ID4 promotes the production of
pro-angiogenic cytokines in BC cells, leading to en-
hanced endothelial cell proliferation and migration [28,
30]. Because the onset of angiogenic switch, identified as
the formation of a high-density vessel network, is closely
associated with the transition to malignancy and is regu-
lated by infiltrating macrophages in primary mammary
tumours [5], we investigated whether ID4 promotes
angiogenesis by influencing the behaviour of macro-
phages. We first evaluated whether any association
existed between ID4 protein expression and infiltrating
TAMs in human BC by staining a series of 62 TNBCs
for ID4 protein and for the widely used macrophage
marker CD68 [15, 35]. The choice of TNBC was based
on evidence that increased ID4 expression is specific to
this subtype, characterised by the absence of oestrogen
receptor, PgR and HER2 receptors, and mostly
attributable to the BLBC molecular subtype, as reviewed
by Baker et al. [23]. Expression levels of ID4 in represen-
tative TNBC and BLBC cohorts are shown in
Additional file 3: Figure S1. Pathological characteristics
of the 62 analysed TNBC cases are included in
Additional file 2: Table S1.
In agreement with the literature [18, 28], we observed
that ID4 protein was detectable in 75% of the analysed
specimens. On the basis of protein expression, we
divided the analysed tumours into low expressers
(comprising negative tumours and tumours scored as 1+)
and high expressers (comprising tumours scored as
2+ and 3+). We observed that high CD68 protein expres-
sion was significantly associated with the ID4 high ex-
presser group (P = 0.028) (Fig. 1a). Representative images
of TNBC showing high or low protein levels of ID4 and
CD68 are shown in Fig. 1b. ID4 and CD68 proteins were
not associated with other pathological characteristics in
this group of patients.
ID4 expression predicts survival in tumours highly
infiltrated by macrophages
High levels of ID4 expression have been correlated to
decreased survival in TNBC and BLBC [17, 20, 21].
Macrophage infiltration has been correlated to angiogen-
esis in BC, but the study of its prognostic significance
has led to contradictory results, probably because of the
existence of various intratumoural macrophage popula-
tions with different properties [12].
To evaluate ID4 prognostic power in relation to
macrophage infiltration, we interrogated the Kaplan-
Meier Plotter database (www.kmplot.com) [36], which
contains a compendium of studies with gene expression
and relative survival data for BLBCs. Interestingly, we
observed that high ID4 expression was strongly
associated with low probability of DMFS (n = 232) and
OS (n = 241), specifically in the group of tumours char-
acterised by high expression of CD68 (and therefore
highly infiltrated by macrophages) (Fig. 1c and
Additional file 4: Table S2), whereas no association of
ID4 with survival was present in the low-CD68 group
(Fig. 1d and Additional file 4: Table S2). A similar result
was obtained when a macrophage signature comprising
a subset of eight widely used markers (CD14, CD105,
CD11b, CD68, CD93, CD33, IL-4R and CD163) for the
mononuclear phagocyte system [37] was used to identify
tumours highly infiltrated by macrophages (Fig. 1e and f
and Additional file 5: Table S3). Analysis of gene expres-
sion data from The Cancer Genome Atlas (TCGA) co-
hort of BLBC confirmed that high ID4 expression is
associated to low probability of overall survival specific-
ally in the CD68-high and macrophage signature
(MacSig)-high groups (Additional file 6: Figure S2a–d).
The TCGA cohort allowed us also to assess that ID4 and
CD68 do not associate with the clinical variables T, N
and G (as observed in the TNBC cohort analysed by
IHC and described in the previous paragraph), whereas
ID4 significantly associates with mutated TP53 status
(Additional file 6: Figure S2e). Moreover, because none
of the considered patients from the TCGA cohort re-
ceived neoadjuvant treatment, we can assert that the ob-
served associations are independent of particular
treatment regimens. These results indicated that the
combination of ID4 and macrophage markers represents
a powerful predictive indicator in BLBC.
ID4 expression in breast cancer cells enhances macrophage
motility
On the basis of the observed association between ID4
protein expression and TAMs, we wondered whether
ID4 expression in BC cells influences macrophage re-
cruitment. To address this, CD34+ progenitors from
mouse bone marrow were isolated, differentiated in vitro
to macrophages (Fig. 2a), and evaluated for their migra-
tory capacity in response to BC cells with ID4 expression
depleted or not (Fig. 2b–c). As shown in Fig. 2c, a lower
number of macrophages migrated towards ID4-depleted
(si-ID4) BC cells than that for control (si-SCR) cells.
To evaluate if ID4 expression in BC cells influences the
recruitment of macrophages in vivo, we performed Matrigel
assays. Briefly, Matrigel plugs containing CM from
MDA-MB-468 BC cells, transfected with an expression
Donzelli et al. Breast Cancer Research  (2018) 20:59 Page 5 of 15
vector for HA-tagged ID4 or an empty vector (Fig. 2d and
e), were inoculated subcutaneously in mouse flanks and re-
covered after 7 days. According to previous reports [38,
39], IHC staining of Matrigel plugs with mouse monocyte/
macrophage marker F4/80 showed the presence of F4/80+
cells within regions of massive cellular infiltration inside the
Matrigel. A higher number of F4/80+ cells was observed in
plugs containing CM from ID4-overexpressing cells than
that in control plugs (Fig. 2f–g).
ID4 expression in breast cancer cells modulates the
activation of a pro-angiogenic programme in macrophages
Because one of the major activities exerted by TAMs is





Fig. 1 Inhibitor of differentiation 4 (ID4) protein and macrophage marker CD68 are significantly associated in triple-negative breast cancer (TNBC).
a and b A series of 62 TNBC samples was stained for ID4 protein and for the macrophage marker CD68. ID4 protein expression was considered
positive when we observed an immunoreaction in the cytoplasm and/or nucleus. Staining intensity was evaluated as follows: 0 negative, 1+ mild,
2+ moderate, 3+ strong. ID4 was considered overexpressed when more than 10% of neoplastic cells presented a strong immunoreaction. CD68
staining was scored as the infiltration density and was evaluated as follows: 0 absent, 1+ mild, 2+ moderate, 3+ dense. a Fisher’s exact test demonstrated
that high ID4 and CD68 expression are significantly associated (P= 0.028). b Representative images of TNBC showing high or low protein levels of ID4 or
CD68. c–f Predictive power of ID4 messenger RNA expression for distant metastasis-free survival (DMFS) (N= 232) was evaluated by Kaplan-Meier analysis
in basal-like breast cancer (BLBC) showing high or low CD68 (c and d) or macrophage signature (MacSig) (e and f) levels. Macrophage
signature is composed of eight widely used markers for the mononuclear phagocyte system (CD14, CD105, CD11b, CD68, CD93, CD33, IL4R,
and CD163 [37])
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whether ID4 expression in BC cells affects the expres-
sion of angiogenic genes in macrophages. To this end,
we took advantage of a TLDA containing probes for a
panel of 94 angiogenesis-related genes. Macrophages ob-
tained from differentiation of HL60 cells [40, 41], cul-
tured with CM from MDA-MB-468 cells transfected
with an ID4 expression vector (ID4) or an empty vector
(EV), were evaluated along with control macrophages
cultured in RPMI medium (Fig. 3a and b). In this
experimental setting, we detected 36 expressed genes,
11 of which were modulated in an ID4-dependent
manner (1 downregulated and 10 upregulated genes)
(Additional file 4: Table S3). The ID4-dependent para-
crine induction in macrophages of a subset of these
genes, comprising ephrin B2 (EPHB2), midkine
(MDK), EDIL3 and GRN, was validated by RT-qPCR
(Additional file 7: Figure S4a) and Western blotting
(Additional file 7: Figure S4b). We verified that ID4
overexpression did not affect the expression of these
genes in MDA-MB-468 cells (Additional file 7: Figure S4a,
right panel).
Moreover, using an additional macrophage cell line
(U937), we observed that the expression of selected
ID4-dependent angiogenesis-related genes (EPHB2, GRN
and NRP2) was induced in macrophages cultivated in
CM compared with RPMI medium (Fig. 3c); as expected,
this induction was impaired when CM was derived from
si-ID4 BC cells (Fig. 3c–f ). Interestingly, analysis of
HIF-1A, a master regulator of angiogenesis, revealed






Fig. 2 Inhibitor of differentiation 4 (ID4) expression in breast cancer cells enhances macrophage motility. a Control of differentiation markers by
fluorescence-activated cell sorting analysis in mouse bone marrow-derived macrophages before (T0) and after (T6) culturing in CSF1-rich medium
(L929) for 6 days. b Efficiency of ID4 depletion in the SKBR3 cells used for migration assays, evaluated by Western blotting. c Migratory capacity of
mouse bone marrow-derived macrophages in response to SKBR3 breast cancer cells, depleted (si-ID4) or not depleted (si-SCR) of ID4 expression,
evaluated by Transwell assay. d Efficiency of hemagglutinin (HA)-tagged ID4 overexpression (ID4-HA) compared with that of empty vector transfection
(EV) evaluated by using an anti-HA antibody in Western blot analysis. ID4-HA and EV MDA-MB-468 cells were used to prepare conditioned media (CM)
for in vivo Matrigel assay. e Schematic representation of Matrigel assay. f and g IHC analysis of mouse macrophage marker F4/80 on Matrigel plugs
containing the indicated CM and recovered from mouse flanks at day 7 after inoculation. Counts of F4/80+ cells are indicated in (g). Results from at
least three biological replicates are shown. Data are presented as mean ± SEM. ***P < 0.0005 calculated by two-tailed t test








Fig. 3 Inhibitor of differentiation 4 (ID4) expression in breast cancer cells leads to the activation of an angiogenic programme in macrophages. a
Expression matrix representing a panel of angiogenic factors evaluated using TaqMan Low-Density Arrays (TLDA) in macrophages obtained by
1,25-dihydroxyvitamin D3 (VitD3)-mediated differentiation of HL60 cells and subsequently cultured in RPMI medium or in conditioned media (CM)
from control (EV) or ID4-overexpressing (ID4) MDA-MB-468 breast cancer cells. b Western blot showing ID4-HA overexpression in MDA-MB-468
cells. c Selected genes modulated in the arrays were evaluated by RT-qPCR in macrophages obtained from VitD3-mediated differentiation of
U937 cells and subsequently cultivated in RPMI medium (CTR) or in CM from control (CM si-SCR) or ID4-depleted (CM si-ID4) MDA-MB-468 cells. d
Western blot analysis showing the level of ID4 protein after transfection of the indicated small interfering RNAs (siRNAs) in MDA-MB-468 cells. e–g
Western blot analysis of ephrin B2 (EphB2), granulin (GRN) and hypoxia-inducible factor (HIF)-1A proteins in differentiated U937 cells cultured in CM
si-SCR or CM si-ID4 from MDA-MB-468 cells. h Immunofluorescence analysis of HIF-1A protein performed in differentiated U937 cells cultured in the
presence of CM si-SCR or CM si-ID4 from MDA-MB-468 cells. i Western blotting showing the efficiency of vascular endothelial growth factor A (VEGFA)
depletion by siRNA transfection in MDA-MB-468 cells used to prepare CM used in experiments shown in (j). j RT-qPCR analysis of the indicated
messenger RNAs in U937 macrophages cultivated in the presence of CM from control (si-SCR) or VEGFA-depleted (si-VEGFA) MDA-MB-468 cells. k
RT-qPCR analysis of the indicated genes in differentiated U937 cells cultivated in RPMI medium or in CM from MDA-MB-468 cells in the presence of
VEGFA blocking antibody (Ab) or a control Ab. Specifically, VEGFA blocking Ab or control Ab were incubated with CM for 30 minutes at room
temperature and CM plus Ab was subsequently used to culture U937 cells for 48 hours. Results from at least three biological replicates are shown.
Data are presented as mean ± SEM. *P < 0.05, **P < 0.005, ***P < 0.0005 calculated by two-tailed t test
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macrophages depends on the level of ID4 expression in
BC cells (Fig. 3c, g and h and Additional file 7: Figure
S4c). Altogether, these results showed that high ID4 ex-
pression in BC cells is associated with the activation of a
pro-angiogenic programme in macrophages.
Because the expression of the angiogenesis-related
genes in macrophages depends on the expression of ID4
in BC cells, we reasoned that a soluble factor, secreted in
an ID4-dependent manner from BC cells, is probably re-
sponsible for the observed gene expression reprogram-
ming of macrophages. In this regard, we recently
reported that ID4 protein promotes the synthesis of
pro-angiogenic isoforms of VEGFA at the expense of the
anti-angiogenic ones in BC cells [30]. We then explored
whether VEGFA was responsible for the observed ef-
fects. We first cultured differentiated U937 cells in CM
from VEGFA-depleted (si-VEGFA) or control (si-SCR)
BC cells. Analysis of a panel of angiogenesis-related fac-
tors evidenced a partial decrease of their expression after
VEGFA depletion (Fig. 3I and j). Next, we observed that
the addition of VEGFA blocking antibody to the CM
from BC cells subsequently used to culture U937 cells
partially impaired the induction of this panel of
angiogenesis-related factors (Fig. 3k). These results indi-
cate that ID4-dependent gene expression modulation in
macrophages is at least in part under the control of
VEGFA signalling.
ID4 expression in breast cancer cells downregulates
anti-angiogenic microRNAs in macrophages
It has been extensively reported that the angiogenic
programme is tightly controlled also at the post-tran-
scriptional level by miRNAs in cancer. To explore
whether the ID4-dependent reprogramming of macro-
phages also involved miRNAs, we evaluated the expres-
sion of members of the miR-15/107 group, which were
previously correlated to angiogenesis in vertebrates and
reported to target GRN and HIF-1B [42–47].
We observed that miR-107, miR-15b and miR-195 are
downregulated in macrophages cultured with CM from
ID4-overexpressing BC cells (CM ID4) compared with
macrophages cultured with CM from BC cells with con-
trol empty vector (CM EV) (Additional file 5: Figure S5a).
On the contrary, expression of these miRNAs was recov-
ered in the presence of CM from si-ID4 BC cells in two
macrophage cell lines (Fig. 4a and b and Additional file 8:
Figure S5b–e). We evaluated the expression of miR-96,
which exhibits oncogenic activity in BC [48], as a control,
and we observed that it shows a trend opposite to that of
miR-107 (Fig. 4c). Recovery of miR-107, miR-15b and
miR-195 expression was also observed in U937 cells cul-
tured in the presence of CM from VEGFA-depleted BC
cells (Additional file 8: Figure S5f ), indicating that
VEGFA signalling also controls, at least in part,
miRNA expression in TAMs.
Time-course analysis of macrophages cultured with
CM from BC cells revealed downregulation of these
miRNAs (Fig. 4d and e and Additional file 8: Figure
S5f ). Analysis of pre-miR-107 expression in the same
conditions highlighted that decrease of mature miR-107
was accompanied by an accumulation of its precursor
(Fig. 4f ), suggesting an inhibition of the processing of
this miRNA in the presence of CM from BC cells.
Altogether, these results indicated that expression of ID4
in BC cells leads to a paracrine downregulation of
miR-107, miR-15b and miR-195 in macrophages.
Next, we focused on miR-107, which shows the stron-
gest ID4-dependent paracrine downregulation in macro-
phages, and evaluated whether it affects the expression
of GRN and HIF-1B, two well-established targets [44,
49]. To this end, we inhibited miR-107 in U937 cells by
transfecting an LNA oligonucleotide (Fig. 4g). As shown
in Fig. 4h, miR-107 inhibition recovered GRN and
HIF-1B protein expression, mimicking the effect of
si-ID4 BC-derived CM. We also observed induced pro-
tein expression of EphB2 and HIF-1A (Fig. 4h), which,
as the majority of the angiogenesis-related factors that
are activated in an ID4-dependent paracrine manner in
macrophages, are predicted to be targeted by the
miR-15/107 group members (Additional file 5: Table S3).
To further investigate the relevance of miR-107 down-
regulation associated with CM, we overexpressed
miR-107 using mimic oligonucleotides in macrophages
cultured with CM from MDA-MB-468 BC cells (Fig. 4i).
As shown in Fig. 4j and k, the forced expression of
miR-107 led to decreased GRN mRNA and protein
levels. Similar results were observed for HIF-1A
(Additional file 8: Figure S5g and h). Our results indi-
cated that the expression of angiogenesis-related genes
is strictly controlled by the activity of the ID4-dependent
miR-107 in macrophages.
Granulin expression markedly increases the angiogenic
potential of macrophages
Among the ID4-dependent angiogenesis-related genes
upregulated in macrophages, GRN particularly attracted
our attention, because this growth factor is specifically
expressed in TNBC and BLBC [50] and has recently
been correlated to tumour angiogenesis in mesothelioma
[51]. In macrophages, GRN has been reported to control
cytokine production [32], but its effect on the angiogenic
potential of these cells has not been explored yet.
To evaluate the ability of GRN to confer angiogenic
potential to macrophages, we performed in vivo angio-
genic assays. To this end, a full-length GRN expression
vector, containing 5′- and 3′-UTRs, or control EV was
transfected in U937-derived macrophages, which were
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then cultured with RPMI or CM from MDA-MB-468
cells. As shown in Fig. 5a and b, although GRN mRNA
expression levels were comparable between RPMI and
CM conditions, GRN protein overexpression was ob-
served only in macrophages cultured with CM. This re-
sult further underlined that GRN expression in
macrophages is strictly controlled at the translational
level and that its protein expression is obtained only in
the presence of CM, possibly as a consequence of
miR-107 downregulation (as shown in Fig. 4d and e).
We then evaluated the angiogenic potential of mac-
rophages transfected with GRN or EV and cultured in




Fig. 4 Inhibitor of differentiation 4 (ID4) expression in breast cancer cells leads to the paracrine downregulation of miR-107 in macrophages. a
and b RT-qPCR analysis to evaluate the expression of miR-107 in macrophages obtained from 1,25-dihydroxyvitamin D3 (VitD3)-mediated differentiation of
HL60 (a) and U937 (b) cells and subsequently cultivated in conditioned media (CM) from control (si-SCR) or ID4-depleted (si-ID4) MDA-MB-468 cells. c
RT-qPCR for miR-96 in U937-derived macrophages as in (b). d and e RT-qPCR analysis of miR-107 in peripheral blood-derived macrophages (PBD-M) (d)
and U937-derived (e) macrophages cultivated in RPMI medium (CTR) or in CM from, respectively, SKBR3 and MDA-MB-468 cells for the indicated time
points. f RT-qPCR for pre-miR-107 in U937 cells as in (e). g RT-qPCR analysis of miR-107 levels in differentiated U937 cells transfected with locked nucleic
acid (LNA) antisense oligonucleotide directed to miR-107. h Western blot analysis of the indicated proteins in differentiated U937 cells transfected with
LNA antisense oligonucleotide directed to miR-107. i and jmiR-107 (i) and granulin (GRN) (j) expression levels evaluated by RT-qPCR in HL60 and U937
cells transfected with control mimic or miR-107 mimic oligonucleotides. k Western blot analysis of GRN in HL60 and U937 cells transfected with control
mimic or miR-107 mimic oligonucleotides. Results from at least three biological replicates are shown. Data are presented as mean ± SEM. *P< 0.05,
**P< 0.005, ***P< 0.0005 calculated by two-tailed t test.






Fig. 5 Modulation of granulin (GRN) expression affects the angiogenic potential of macrophages. a Western blot analysis of GRN in U937 cells
transfected with a GRN expression vector or an empty vector (EV) and cultured in the presence of RPMI medium or conditioned media (CM) from
MDA-MB-468 cells. b RT-qPCR analysis of GRN messenger RNA levels in the same experimental conditions described in (a). c CM from the indicated
experimental conditions were injected into the perivitelline space of zebrafish embryos, and neovascular response originating from the developing
subintestinal plexus was evaluated. Injection of PBS alone or PBS supplemented with recombinant vascular endothelial growth factor A (rhVEGFA) was
used, respectively, as negative and positive controls. Spikes sprouting from subintestinal plexus were counted in at least 42 embryos per condition.
Graph shows the distribution of the population of embryos evaluated for each condition. Representative images are shown in (d). Significance was
evaluated by one-way analysis of variance followed by Sidak’s multiple comparisons test using GraphPad software (GraphPad, La Jolla, CA,
USA). ***P< 0.0005. e Western blot analysis of GRN in U937 cells transfected for 8 hours with control small interfering RNA (si-SCR) or three different
GRN-targeting siRNAs (si-GRN_#1,_#2,_#3) and subsequently cultured in the presence of CM from MDA-MB-468 cells for 72 hours. f and g Tube-formation
assays involving EA.Hy926 endothelial cells performed in the presence of CM from the conditions indicated in (e). RPMI medium, supplemented (rhVEGFA)
or not (RPMI) with recombinant VEGFA, was used as a positive or negative control, respectively. Data are presented as mean ± SEM. *P< 0.05, **P< 0.005
calculated by two-tailed t test
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CM from MDA-MB-468 cells using transgenic zebra-
fish embryos expressing enhanced green fluorescent
protein in the entire vasculature. Specifically, Matrigel
plugs containing CM from each experimental condi-
tion were injected into the perivitelline space of zeb-
rafish embryos, and neovascular response originating
from the developing subintestinal plexus was evalu-
ated. Injection of Matrigel plugs containing PBS alone
or PBS supplemented with recombinant VEGFA
(rhVEGFA) was used as a negative and positive con-
trol, respectively. As shown in Fig. 5c and d, we ob-
served a greater number of embryos presenting two
or more spikes sprouting from subintestinal plexus in
the GRN overexpression condition compared with
that in the EV condition. Accordingly, in the GRN
overexpression condition, we also observed a reduced
number of embryos showing one or no spikes (Fig. 5c
and d). No effects on macrophage viability and differ-
entiation were observed in the presence of GRN over-
expression (Additional file 9: Figure S6).
Next, we evaluated the effect of GRN depletion on
macrophage angiogenic potential. To this end, we trans-
fected siRNAs directed to GRN or control siRNAs
(si-SCR) in U937-derived macrophages, which were then
cultured with CM from MDA-MB-468 cells (Fig. 5e).
CM from each experimental condition was then evalu-
ated in tube-formation assays involving the growth of
endothelial cells. Conditions with RPMI medium
supplemented or not with rhVEGFA were included as
positive and negative controls, respectively. As shown in
Fig. 5f and g, GRN depletion led to the significant de-
crease of tube-formation potential.
Discussion
In this study, we demonstrated that expression of ID4 in
BC cells is an important determinant of TAM behaviour.
High ID4 expression in BC cells indeed is able to cause
not only macrophage recruitment but also the repro-
gramming of macrophage gene expression (Fig. 6). Spe-
cifically, we observed that ID4 modulates a panel of
angiogenesis-associated factors, among which there is an
important regulator of inflammation, GRN [32, 52].
It has been reported that GRN directly binds to
tumour necrosis factor (TNF) receptors and counteracts
the TNF-mediated inflammatory signalling pathway.
GRN also induces regulatory T-cell populations and
IL-10 production and inhibits CXCL9 and CXCL10 che-
mokine release. It will be interesting to evaluate in fur-
ther studies whether ID4-dependent GRN induction
occurring in macrophages has an immunomodulatory
effect in BC. Analysis of tumour tissues from a cohort of
patients with BC revealed that high GRN expression cor-
related with the most aggressive triple-negative BLBC
and reduced patient survival [50].
In addition to the angiogenesis-related factors induced in
an ID4-dependent manner, we observed in macrophages a
Fig. 6 Summary scheme of the identified paracrine signalling from breast cancer (BC) cells to macrophages. Briefly, breast cancer cells expressing
high levels of inhibitor of differentiation 4 (ID4) protein produce vascular endothelial growth factor A (VEGFA) and other factors implicated in the
induction of an angiogenic programme in neighbouring macrophages. In parallel to the induction of angiogenesis-related messenger RNAs, we
observed a decrease of miR-15b/107 group members, with consequent release of the expression of its targets, as transcription factor hypoxia-
inducible factor (HIF)-1A and granulin (GRN). TAM Tumour-associated macrophage
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similar increase of transcription factor HIF-1. HIF-1 has
previously been reported to be strongly involved in TAM
pro-tumourigenic activities. Of note, the majority of the
angiogenesis-related factors that we have identified present
HIF-1 consensus sequences in their promoter regions and
therefore could be subjected to HIF-1-dependent transacti-
vation (Additional file 9: Table S3).
Another important aspect of this study is the identifi-
cation of VEGF, whose isoform synthesis is controlled by
ID4 in BC cells [30], as one of the soluble factors partici-
pating in the paracrine activation of the angiogenic
programme in co-cultured macrophages. We have in-
deed recently identified that VEGFA isoform expression
is controlled in BC cells by a ribonucleoprotein complex
containing, in addition to ID4, the splicing factor SRSF1,
the mutant p53 protein and the long non-coding RNA
MALAT1 [30]. This complex favours the production of
VEGF121 and VEGF165 isoforms. Because the addition
of blocking antibodies directed to VEGFA in CM from
BC cells significantly reduced the angiogenic programme
activation in macrophages, it is highly probable that this
programme depends on the ribonucleoprotein complex
controlling VEGFA expression in BC cells. Interestingly,
we showed that blocking of VEGFA prevents
CM-dependent activation of EPHB2 and NRP2, among
others. Of note, both these genes have been reported to
participate in the enhancement of VEGFA signalling
through VEGFR2 [53–55]. Activation of EPHB2 and
NRP2 then could represent a mechanism for VEGFA
signalling amplification in macrophages, because an in-
crease of these molecules will probably lead to a more
efficient response to the VEGFA present in the CM (in
our experimental system) and in the in vivo tumour
microenvironment.
Finally, we identified an additional layer of control of
the angiogenesis-related genes in macrophages (i.e., the
post-transcriptional layer). Indeed, among the identified
angiogenesis-related factors, HIF-1 and GRN are interest-
ingly controlled by miR-107, whose expression is down-
regulated in macrophages in an ID4-dependent manner.
miR-107 and another miRNA of this family (miR-195) that
we have found downregulated in an ID4-dependent man-
ner in macrophages were previously shown to have
tumour-suppressive properties in BC [56–59]. Our study
elucidates a novel role for these miRNAs in the control of
the angiogenic programme in TAMs.
Conclusion
Taken together, our results reveal that ID4 protein, pre-
viously shown to control the stem-like phenotype of nor-
mal and transformed mammary epithelial cells, also
controls the angiogenic potential in breast cancer
through the modulation of tumor-associated macro-
phage activity. The identified paracrine signaling may
represent a promising basis for the development of ther-
apies aimed at disrupting the cross-talk between cancer
cells and tumor stroma.
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Additional file 1: Figure S3 Growth curve of MDA-MB-468 cells
depleted (si-ID4) or not (si-SCR) of ID4 expression by siRNA transfection
(a). Cells were transfected for 16 hours, and then equal numbers of cells
were plated and counted at the indicated time points. Efficiency of ID4
depletion at 48 hours and 72 hours was evaluated by Western blotting
(b). (PDF 4554 kb)
Additional file 2: Table S1 Characteristics of patients selected for the
analysis of ID4 protein expression. (DOCX 17 kb)
Additional file 3: Figure S1. Comparison of ID4 mRNA expression in
basal-like breast cancer (BLBC) and triple-negative breast cancer (TNBC)
versus all other breast cancer subtypes (Others) in the indicated representative
datasets [19, 22, 60]. (PDF 143 kb)
Additional file 4: Table S2 Predictive power of ID4, CD68 and the
macrophage signature (MacSig) comprising eight widely used markers
(CD14, CD105, CD11b, CD68, CD93, CD33, IL4R, CD163) for the
mononuclear phagocyte system [37]. Analysis was performed using
datasets deposited in the KMplot database [36]. DMFS Distant metastasis-
free survival, OS Overall survival. (DOCX 21 kb)
Additional file 5: Table S3 mRNAs modulated in an ID4-dependent
manner in differentiated HL60 cells cultured with conditioned medium
from control (CM EV) or ID4-overexpressing (CM ID4) MDA-MB-468 cells.
The presence of HIF-1 consensus sequences on promoters was evaluated
using the LASAGNA-Search web tool (http://biogrid-lasagna.engr.uconn.
edu/lasagna_search/). The presence of putative binding sites for miR-107,
miR-15b and miR-195 on 3′-UTR or coding (CDS) sequences of mRNAs was
evaluated using the miRWalk analysis tool (http://zmf.umm.uni-heidelberg.de/
apps/zmf/mirwalk2/) by selecting the following databases: (1) 3′-UTR
analysis =miRWalk, miRanda, miRDB, miRNAMap, Pictar2, RNA22, RNAhybrid,
TargetScan; and (2) CDS analysis = miRWalk, miRanda, RNA22, RNAhybrid,
TargetScan. (DOCX 22 kb)
Additional file 6: Figure S2. Predictive power of ID4 mRNA expression
for overall survival (OS) was evaluated by Kaplan-Meier analysis on the
TCGA cohort in BLBCs showing high or low CD68 (a and b) or macrophage
signature (MacSig) (c and d) levels. Macrophage signature is composed of
eight widely used markers for the mononuclear phagocyte system (CD14,
CD105, CD11b, CD68, CD93, CD33, IL4R and CD163 [37]). e Evaluation of
association between ID4 or CD68 and the pathological variables T, N, G and
TP53 status in the BLBCs from the TCGA cohort. (PDF 4464 kb)
Additional file 7: Figure S4 a Modulation of selected genes modulated
in the TLDA was validated by RT-qPCR in differentiated HL60 cells
cultured in CM from ID4-overexpressing (CM ID4-HA) or control (CM EV)
MDA-MB-468 cells (left panel). The same transcripts were analysed in
MDA-MB-468 cells transfected with ID4-HA expression vector (ID4-HA) or
control empty vector (EV) (right panel). b Expression of EphB2, MDK and
GRN protein evaluated by Western blotting on lysates from differentiated
HL60 cells cultured as in (a); secreted GRN (sGRN) was evaluated on CM
from differentiated HL60 cells in the same conditions. c HIF1A protein
expression evaluated by Western blotting in differentiated U937 cells
cultured in RPMI medium or in CM from SKBR3 cells stably interfered for
ID4 expression (sh-ID4) or control cells (sh-CTR). (PDF 1320 kb)
Additional file 8: Figure S5 a Expression of miR-107, miR-15b and
miR-195 in differentiated HL60 cells cultured with CM from control (CM
EV) or ID4-overexpressing (CM ID4) MDA-MB-468 cells. b–e Expression of
miR-15b and miR-195 in HL60 and U937 cells cultured with CM from
control (si-SCR) or ID4-depleted (si-ID4) BC cells. f miR-107, miR-15b and
miR-195 expression evaluated by RT-qPCR in differentiated U937 cells
cultured with CM from MDA-MB-468 cells depleted or not of VEGFA
expression. VEGFA interference efficiency is shown in Fig. 3i. g Expression
levels of miR-15b and miR-195 in differentiated U937 cells cultivated in
RPMI medium (CTR) or CM from MDA-MB-468 cells for the indicated time
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points. h and i HIF1A mRNA (h) and protein (i) expression evaluated,
respectively, by RT-qPCR and immunofluorescence in differentiated U937
cells transfected with control mimic or miR-107 mimic and cultured in
the presence of CM from MDA-MB-468 cells for 48 hours. (PDF 2150 kb)
Additional file 9: Figure S6 Differentiated U937 cells transfected with
an empty vector (EV) or a granulin (GRN) expression vector and subsequently
cultivated in the presence of CM from MDA-MB-468 cells were evaluated for
their differentiation state (percentage of CD11b+ cells) (a) and for their viability
(b) by, respectively, FACS analysis and ATPlite assay at the indicated time
points after CM addition. c Overexpression of GRN evaluated by Western
blotting. (PDF 141 kb)
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